- Salix Pharmaceuticals introduces Rx topical foam to treat a form of inflammatory bowel disease
- Takeda starts phase-3 trials of vedolizumab
- FDA pushes back target date for review of Takeda drug in patients with ulcerative colitis
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
DEERFIELD, Ill. — An expert panel at the Food and Drug Administration has given a thumbs-up to an experimental drug made by Takeda Pharmaceutical Co. for treating ulcerative colitis and Crohn's disease, the drug maker said.
Takeda said the FDA's Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committee voted in favor of approval for vedolizumab in adults with moderately to severely active UC or Crohn's. A favorable advisory committee vote does not guarantee FDA approval of a drug, but the agency usually follows the votes when deciding whether or not to grant approval.
"People with ulcerative colitis or Crohn's disease are in need of additional treatment options, as many patients lose response to currently available treatments," Takeda VP general medicine Asit Parikh said. "Vedolizumab was designed to treat inflammation of the [gastrointestinal] tract and, if approved, may offer an additional option for patients suffering from ulcerative colitis or Crohn's disease."